BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22023317)

  • 1. Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22023317
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous CCR5-modified CD4 T-cells effective in HAART nonresponders.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22132424
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging race to cure HIV infections.
    Cohen J
    Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted gene editing enters clinic.
    Ledford H
    Nature; 2011 Mar; 471(7336):16. PubMed ID: 21368795
    [No Abstract]   [Full Text] [Related]  

  • 5. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.
    Holt N; Wang J; Kim K; Friedman G; Wang X; Taupin V; Crooks GM; Kohn DB; Gregory PD; Holmes MC; Cannon PM
    Nat Biotechnol; 2010 Aug; 28(8):839-47. PubMed ID: 20601939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
    Tebas P; Stein D; Tang WW; Frank I; Wang SQ; Lee G; Spratt SK; Surosky RT; Giedlin MA; Nichol G; Holmes MC; Gregory PD; Ando DG; Kalos M; Collman RG; Binder-Scholl G; Plesa G; Hwang WT; Levine BL; June CH
    N Engl J Med; 2014 Mar; 370(10):901-10. PubMed ID: 24597865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
    Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
    J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cell surface CCR5 density and virus load in persons infected with human immunodeficiency virus type 1.
    Marmor M; Krowka J; Goldberg JD
    J Infect Dis; 2000 Oct; 182(4):1284-6. PubMed ID: 10979936
    [No Abstract]   [Full Text] [Related]  

  • 13. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
    Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling HIV infection: HIV co-receptor gets the finger.
    Kelleher AD; Purcell DF
    Immunol Cell Biol; 2008; 86(8):641-2. PubMed ID: 18779839
    [No Abstract]   [Full Text] [Related]  

  • 18. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 19. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.